Sylvaine Cartot‐Cotton

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden et al. · Nature Communications · 2022 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically‐based pharmacokinetic modelling: application to docetaxel

Hoai‐Thu Thai, Florent Mazuir, Sylvaine Cartot‐Cotton et al. · British Journal of Clinical Pharmacology · 2015 · 44 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

Eric Van Cutsem, David Khayat, Chris Verslype et al. · European Journal of Cancer · 2012 · 36 citations · Full text

Medicine, Oncology, Pharmacology +14

First‐in‐human trial of the PI3Kβ‐selective inhibitor SAR260301 in patients with advanced solid tumors

Philippe L. Bédard, Michael A. Davies, Scott Kopetz et al. · Cancer · 2017 · 34 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Aditya Bardia, Javier Cortés, Sara A. Hurvitz et al. · Therapeutic Advances in Medical Oncology · 2022 · 28 citations · Full text

Medicine, Oncology, Pharmacology +16